{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:37:59Z","timestamp":1787614679457,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:p>\n                    Well\u2010tolerated, ribavirin\u2010free, pangenotypic hepatitis C virus (HCV) treatments for transplant recipients remain a high priority. Once\u2010daily glecaprevir\/pibrentasvir demonstrates high rates of sustained virologic response at 12 weeks posttreatment (SVR12) across all major HCV genotypes (GTs). This trial evaluated the safety and efficacy of glecaprevir\/pibrentasvir for patients with chronic HCV GT1\u20106 infection who had received a liver or kidney transplant. MAGELLAN\u20102 was a phase 3, open\u2010label trial conducted in patients who were \u22653 months posttransplant. Patients without cirrhosis who were HCV treatment\u2010naive (GT1\u20106) or treatment\u2010experienced (GT1, 2, 4\u20106; with interferon\u2010based therapy with or without sofosbuvir, or sofosbuvir plus ribavirin) received glecaprevir\/pibrentasvir (300\/120 mg) once daily for 12 weeks. The primary endpoint compared the percentage of patients receiving glecaprevir\/pibrentasvir with SVR12 to a historic SVR12 rate based on the standard of care. Safety of glecaprevir\/pibrentasvir was assessed. In total, 80 liver transplant and 20 kidney transplant patients participated in the trial. Most patients had no or minimal fibrosis (80% had fibrosis scores F0\u2010F1) and were infected with HCV GT1 (57%) or GT3 (24%). The overall SVR12 was 98% (n\/N = 98\/100; 95% confidence interval, 95.3%\u2013100%), which exceeded the prespecified historic standard\u2010of\u2010care SVR12 threshold of 94%. One patient experienced virologic failure. One patient discontinued because of an adverse event considered to be unrelated to treatment; this patient achieved SVR12. Adverse events were mostly mild in severity, and laboratory abnormalities were infrequent.\n                    <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic>\n                    Once\u2010daily glecaprevir\/pibrentasvir for 12 weeks is a well\u2010tolerated and efficacious, ribavirin\u2010free treatment for patients with chronic HCV GT1\u20106 infection who have received a liver or kidney transplant. (ClinicalTrials.gov NCT02692703.) (H\n                    <jats:sc>epatology<\/jats:sc>\n                    2018; 00:000\u2010000).\n                  <\/jats:p>","DOI":"10.1002\/hep.30046","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T16:11:46Z","timestamp":1524154306000},"page":"1298-1307","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":167,"title":["Glecaprevir\/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection"],"prefix":"10.1097","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2290-4580","authenticated-orcid":false,"given":"Nancy","family":"Reau","sequence":"first","affiliation":[{"name":"Rush University Medical Center,Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Y.","family":"Kwo","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine,Palo Alto,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Rhee","sequence":"additional","affiliation":[{"name":"AbbVie Inc.,North Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Brown","sequence":"additional","affiliation":[{"name":"Center for Liver Disease and Transplantation,Weill Cornell Medical College,New York,NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4754-828X","authenticated-orcid":false,"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies,King's College Hospital NHS Foundation Trust,London,UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Angus","sequence":"additional","affiliation":[{"name":"University of Melbourne,Melbourne,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Gane","sequence":"additional","affiliation":[{"name":"New Zealand Liver Transplant Unit,Auckland City Hospital,Auckland,New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia\u2010Horng","family":"Kao","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital,Taipei,Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvez S.","family":"Mantry","sequence":"additional","affiliation":[{"name":"The Liver Institute at Methodist Dallas,Dallas,TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mutimer","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital and NIHR Liver Biomedical Research Unit,Birmingham,UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4898-7778","authenticated-orcid":false,"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[{"name":"University of Pennsylvania,Philadelphia,PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tram T.","family":"Tran","sequence":"additional","affiliation":[{"name":"Cedars Sinai Medical Center,Los Angeles,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran B.","family":"Hu","sequence":"additional","affiliation":[{"name":"AbbVie Inc.,North Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Gulati","sequence":"additional","affiliation":[{"name":"AbbVie Inc.,North Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preethi","family":"Krishnan","sequence":"additional","affiliation":[{"name":"AbbVie Inc.,North Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily O.","family":"Dumas","sequence":"additional","affiliation":[{"name":"AbbVie Inc.,North Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Porcalla","sequence":"additional","affiliation":[{"name":"AbbVie Inc.,North Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy S.","family":"Shulman","sequence":"additional","affiliation":[{"name":"AbbVie Inc.,North Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"AbbVie Inc.,North Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvajit","family":"Samanta","sequence":"additional","affiliation":[{"name":"AbbVie Inc.,North Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Trinh","sequence":"additional","affiliation":[{"name":"AbbVie Inc.,North Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[{"name":"Liver Unit, Hospital Clinic, CIBEREHD, IDIBAPS,University of Barcelona,Barcelona,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,7,25]]},"reference":[{"key":"hep30046-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: an up\u2010date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","year":"2016","journal-title":"World J Gastroenterol"},{"key":"hep30046-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJM199603283341302","article-title":"Long\u2010term outcome of hepatitis C infection after liver transplantation","volume":"334","year":"1996","journal-title":"N Engl J Med"},{"key":"hep30046-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/jhep.2002.31773","article-title":"Hepatitis C virus kinetics during and immediately after liver transplantation","volume":"35","year":"2002","journal-title":"Hepatology"},{"key":"hep30046-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1053\/j.gastro.2012.02.011","article-title":"Viral hepatitis in liver transplantation","volume":"142","year":"2012","journal-title":"Gastroenterology"},{"key":"hep30046-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.21090","article-title":"Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation","volume":"43","year":"2006","journal-title":"Hepatology"},{"key":"hep30046-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"The association between hepatitis C infection and survival after orthotopic liver transplantation","volume":"122","year":"2002","journal-title":"Gastroenterology"},{"key":"hep30046-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jvh.12148","article-title":"Meta\u2010analysis of observational studies: hepatitis C and survival after renal transplant","volume":"21","year":"2014","journal-title":"J Viral Hepat"},{"key":"hep30046-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"423","DOI":"10.5414\/CNP71423","article-title":"Geographical prevalence, risk factors and impact of hepatitis B and C after renal transplantation","volume":"71","year":"2009","journal-title":"Clin Nephrol"},{"key":"hep30046-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.transproceed.2009.01.074","article-title":"Impact of hepatitis B and C virus infections on kidney transplantation: a single center experience","volume":"41","year":"2009","journal-title":"Transplant Proc"},{"key":"hep30046-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2215\/CJN.07940716","article-title":"Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis","volume":"12","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"hep30046-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1399-0012.2012.01635.x","article-title":"Histological evolution of hepatitis C virus infection after renal transplantation","volume":"26","year":"2012","journal-title":"Clin Transplant"},{"key":"hep30046-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/ajkd.2001.28576","article-title":"Hepatitis C virus infection and renal transplantation","volume":"38","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"hep30046-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrneph.2015.5","article-title":"Hepatitis C and its impact on renal transplantation","volume":"11","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"hep30046-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1600-6143.2007.02126.x","article-title":"Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation","volume":"8","year":"2008","journal-title":"Am J Transplant"},{"key":"hep30046-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","year":"2009","journal-title":"Hepatology"},{"key":"hep30046-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"key":"hep30046-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/lt.24416","article-title":"Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection","volume":"22","year":"2016","journal-title":"Liver Transpl"},{"key":"hep30046-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon\u2010free antiviral regimen for HCV after liver transplantation","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"hep30046-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/tri.12896","article-title":"Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study","volume":"30","year":"2017","journal-title":"Transpl Int"},{"key":"hep30046-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post\u2013liver transplantation recurrence","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep30046-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment with ledipasvir\u2010sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial","volume":"166","year":"2017","journal-title":"Ann Intern Med"},{"key":"hep30046-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.29258","article-title":"Safety and efficacy of current direct\u2010acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV\u2010TARGET study","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"hep30046-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/ajt.13518","article-title":"Efficacy and safety of sofosbuvir\u2010based antiviral therapy to treat hepatitis C virus infection after kidney transplantation","volume":"16","year":"2016","journal-title":"Am J Transplant"},{"key":"hep30046-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/ajt.13620","article-title":"Successful treatment of hepatitis C in renal transplant recipients with direct\u2010acting antiviral agents","volume":"16","year":"2016","journal-title":"Am J Transplant"},{"key":"hep30046-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4254\/wjh.v7.i1.78","article-title":"Hepatitis C and kidney disease: an overview and approach to management","volume":"7","year":"2015","journal-title":"World J Hepatol"},{"key":"hep30046-bib-0028-20241017","first-page":"e02558","article-title":"In vitro antiviral activity and resistance profile of the next\u2010generation hepatitis C virus NS5A inhibitor pibrentasvir","volume":"61","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"hep30046-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/j.gastro.2016.07.020","article-title":"High efficacy of ABT\u2010493 and ABT\u2010530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis","volume":"151","year":"2016","journal-title":"Gastroenterology"},{"key":"hep30046-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20106 without cirrhosis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep30046-bib-0032-20241017","first-page":"417","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30046-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir\u2010pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"hep30046-bib-0034-20241017","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.29081","article-title":"Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct\u2010acting antiviral treatment","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"hep30046-bib-0035-20241017","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION\u20101): a single\u2010arm, open\u2010label, multicentre phase 3 trial","volume":"17","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"hep30046-bib-0036-20241017","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"hep30046-bib-0037-20241017","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open\u2010label, randomised, phase 2 trial","volume":"16","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"Suppl.","key":"hep30046-bib-0038-20241017","first-page":"S500","article-title":"Pooled resistance analysis in HCV genotype 1\u20106\u2010infected patients treated with glecaprevir\/pibrentasvir in phase 2 and 3 clinical trials","volume":"66","year":"2017","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.30046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.30046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.30046","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201810000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T19:27:04Z","timestamp":1729193224000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201810000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,25]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.30046","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733079093.793568738","asserted-by":"object"}]},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,25]]},"assertion":[{"value":"2018-02-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}